AbbVie Inc.
ABBVAPI behind this page
ABBV Q1 2026 request
Playground key active
/api/financials?ticker=ABBV&year=2026&quarter=1
Pick an endpoint and run the request.Income Statement
| Metric | Q1 2026 | Q1 2025 | YoY |
|---|---|---|---|
| Revenue | 15,002 | 13,343 | +12.4% |
| Cost of Revenue | 4,218 | 4,002 | +5.4% |
Show Equity Components breakouts |
|||
| Accumulated Gain Loss Cash Flow Hedge Including Noncontrolling Interest · Foreign Exchange Forward | 7 | 1 | +600.0% |
| Selling, General & Administrative | 3,578 | 3,293 | +8.7% |
| Research And Development Expense Excluding Acquired In Process Cost | 2,472 | 2,067 | +19.6% |
| Research And Development Asset Acquired Other Than Through Business Combination Written Off | 744 | 248 | +200.0% |
Show Counterparty Name breakouts |
|||
| Other Collaboration Arrangements · Collaborative Arrangement | 703 | 246 | +185.8% |
| RemeGen | 650 | — | — |
| Total Costs & Expenses | 11,012 | 9,610 | +14.6% |
| Operating Income | 3,990 | 3,733 | +6.9% |
| Interest Income Expense Nonoperating Net | 645 | 627 | +2.9% |
Show Equity Components breakouts |
|||
| Accumulated Gain Loss Cash Flow Hedge Including Noncontrolling Interest · Treasury Lock | -6 | -5 | -20.0% |
| Aoci Derivative Qualifying As Hedge Excluded Component Parent · Net Investment Hedging | -37 | -34 | -8.8% |
| Other Non-Operating Income (Expense) | 2,306 | 1,445 | +59.6% |
| Income Before Taxes | 1,039 | 1,661 | -37.4% |
| Income Tax Expense (Benefit) | 342 | 372 | -8.1% |
Show Equity Components breakouts |
|||
| Accumulated Gain Loss Cash Flow Hedge Including Noncontrolling Interest · Reclassification Out Of Accumulated Other Comprehensive Income | 3 | 2 | +50.0% |
| Aoci Derivative Qualifying As Hedge Excluded Component Parent · Net Investment Hedging | 8 | 7 | +14.3% |
| Net Income | 697 | 1,289 | -45.9% |
| Net Income Loss Attributable To Noncontrolling Interest | 2 | 3 | -33.3% |
| Net Income | 695 | 1,286 | -46.0% |
Show Equity Components breakouts |
|||
| Accumulated Gain Loss Cash Flow Hedge Including Noncontrolling Interest · Reclassification Out Of Accumulated Other Comprehensive Income | -4 | 2 | -300.0% |
| Aoci Derivative Qualifying As Hedge Excluded Component Parent · Net Investment Hedging | 29 | 27 | +7.4% |
| Retained Earnings | 695 | 1,286 | -46.0% |
| EPS (Basic) | 0.39 | 0.72 | -45.8% |
| EPS (Diluted) | 0.39 | 0.72 | -45.8% |
| Wtd Avg Shares (Basic) | 1,770 | 1,768 | +0.1% |
| Wtd Avg Shares (Diluted) | 1,774 | 1,772 | +0.1% |
| Revenue (Q) | — | — | — |
Show Product Lines breakouts |
|||
| All other | 1,025 | 1,253 | -18.2% |
| Botox Cosmetic · Aesthetics | 668 | 556 | +20.1% |
| Botox Cosmetic · Non Us | 297 | 261 | +13.8% |
| Botox Cosmetic · US | 371 | 295 | +25.8% |
| Botox Therapeutic · Neuroscience | 1,009 | 866 | +16.5% |
| Botox Therapeutic · Non Us | 167 | 143 | +16.8% |
| Botox Therapeutic · US | 842 | 723 | +16.5% |
| Creon · US | 361 | 355 | +1.7% |
| Elahere · Non Us | 38 | 14 | +171.4% |
| Elahere · Oncology | 198 | 179 | +10.6% |
| Elahere · US | 160 | 165 | -3.0% |
| Epkinly · Non Us | 32 | 15 | +113.3% |
| Epkinly · Oncology | 83 | 51 | +62.7% |
| Humira · Immunology | 688 | 1,121 | -38.6% |
| Humira · Non Us | 331 | 377 | -12.2% |
| Humira · US | 357 | 744 | -52.0% |
| Imbruvica · Oncology | 556 | 738 | -24.7% |
| Imbruvica · US | 332 | 529 | -37.2% |
| Juvederm Collection · Aesthetics | 232 | 231 | +0.4% |
| Juvederm Collection · Non Us | 147 | 156 | -5.8% |
| Juvederm Collection · US | 85 | 75 | +13.3% |
| Linzess · Non Us | 11 | 9 | +22.2% |
| Linzess · Other Key Products | 283 | 148 | +91.2% |
| Linzess · US | 272 | 139 | +95.7% |
| Mavyret · Non Us | 168 | 164 | +2.4% |
| Mavyret · Other Key Products | 351 | 306 | +14.7% |
| Mavyret · US | 183 | 142 | +28.9% |
| Other Aesthetics · Aesthetics | 286 | 315 | -9.2% |
| Other Aesthetics · Non Us | 38 | 45 | -15.6% |
| Other Aesthetics · US | 248 | 270 | -8.1% |
| Other Neuroscience · Neuroscience | 125 | 155 | -19.4% |
| Other Neuroscience · Non Us | 79 | 80 | -1.2% |
| Other Neuroscience · US | 46 | 75 | -38.7% |
| Other Oncology · US | 24 | — | — |
| Qulipta · Neuroscience | 296 | 193 | +53.4% |
| Qulipta · Non Us | 46 | 21 | +119.0% |
| Qulipta · US | 250 | 172 | +45.3% |
| Rinvoq · Immunology | 2,119 | 1,718 | +23.3% |
| Rinvoq · Non Us | 714 | 498 | +43.4% |
| Rinvoq · US | 1,405 | 1,220 | +15.2% |
| Skyrizi · Immunology | 4,483 | 3,425 | +30.9% |
| Skyrizi · Non Us | 708 | 506 | +39.9% |
| Skyrizi · US | 3,775 | 2,919 | +29.3% |
| Ubrelvy · Neuroscience | 339 | 240 | +41.2% |
| Ubrelvy · Non Us | 9 | 7 | +28.6% |
| Ubrelvy · US | 330 | 233 | +41.6% |
| Venclexta · Non Us | 429 | 353 | +21.5% |
| Venclexta · Oncology | 770 | 665 | +15.8% |
| Venclexta · US | 341 | 312 | +9.3% |
| Vraylar · Neuroscience | 905 | 765 | +18.3% |
| Vraylar · Non Us | 3 | 2 | +50.0% |
| Vraylar · US | 902 | 763 | +18.2% |
| Vyalev · Neuroscience | 201 | 63 | +219.0% |
| Vyalev · Non Us | 112 | 57 | +96.5% |
| Vyalev · US | 89 | 6 | +1383.3% |
| Interest Income | -72 | -73 | +1.4% |
| Comprehensive Income | 686 | 1,469 | -53.3% |
| Net Income Loss Available To Common Stockholders Basic | 685 | 1,276 | -46.3% |
| Interest Expense | 717 | 700 | +2.4% |
Balance Sheet
| Metric | Q1 2026 | Q1 2025 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 9,391 | 5,175 | +81.5% |
| Accounts Receivable | 12,479 | 12,477 | 0.0% |
| Inventory | 5,049 | 4,526 | +11.6% |
| Prepaid Expense And Other Assets | 6,610 | 5,496 | +20.3% |
| Total Current Assets | 33,529 | 27,675 | +21.2% |
| Non-Current Assets | |||
| Long Term Investments | 268 | 287 | -6.6% |
| Property, Plant & Equipment | 5,687 | 5,237 | +8.6% |
| Goodwill | 35,570 | 35,285 | +0.8% |
| Other Non-Current Assets | 10,536 | 9,192 | +14.6% |
| Total Assets | 136,463 | 136,165 | +0.2% |
| Intangible Assets | 45,601 | 53,198 | -14.3% |
Show Finite Lived Intangible Assets By Major Class breakouts |
|||
| Developed Technology Rights | 44,785 | 51,657 | -13.3% |
| Licensing Agreements | 816 | 1,541 | -47.0% |
| Other Assets | |||
| Intangible Assets Net Excluding Goodwill | 50,873 | 58,489 | -13.0% |
| Current Liabilities | |||
| Long Term Debt And Capital Lease Obligations Current | 8,326 | 3,769 | +120.9% |
| Accounts Payable And Accrued Liabilities Current | 33,774 | 31,041 | +8.8% |
| Total Current Liabilities | 42,100 | 36,403 | +15.6% |
| Non-Current Liabilities | |||
| Deferred Tax Liabilities | 2,332 | 2,582 | -9.7% |
| Other Non-Current Liabilities | 34,111 | 31,191 | +9.4% |
| Other Liabilities | |||
| Long Term Debt And Capital Lease Obligations | 64,532 | 64,527 | 0.0% |
| Minority Interest | 44 | 42 | +4.8% |
| Stockholders' Equity | |||
| Common Stock Value Outstanding | 18 | 18 | 0.0% |
| Treasury Stock Value | -10,611 | -9,137 | -16.1% |
| Additional Paid In Capital Common Stock | 22,962 | 21,808 | +5.3% |
| Retained Earnings | -17,872 | -9,527 | -87.6% |
| Accumulated Other Comprehensive Income | -1,153 | -1,742 | +33.8% |
| Total Stockholders' Equity | -6,656 | 1,420 | -568.7% |
| Stockholders Equity Including Portion Attributable To Noncontrolling Interest | -6,612 | 1,462 | -552.3% |
Show Equity Components breakouts |
|||
| Accumulated Defined Benefit Plans Adjustment Including Portion Attributable To Noncontrolling Interest | -244 | -666 | +63.4% |
| Accumulated Foreign Currency Adjustment Including Portion Attributable To Noncontrolling Interest | -837 | -1,627 | +48.6% |
| Accumulated Gain Loss Cash Flow Hedge Including Noncontrolling Interest | 194 | 285 | -31.9% |
| Accumulated Other Comprehensive Income | -1,153 | -1,742 | +33.8% |
| Additional Paid In Capital | 22,962 | 21,808 | +5.3% |
| Aoci Including Portion Attributable To Noncontrolling Interest | -1,153 | -1,742 | +33.8% |
| Common Stock | 18 | 18 | 0.0% |
| Net investment hedging activities | -266 | 266 | -200.0% |
| Noncontrolling Interest | 44 | 42 | +4.8% |
| Retained Earnings | -17,872 | -9,527 | -87.6% |
| Treasury Stock Common | -10,611 | -9,137 | -16.1% |
| Total Liabilities & Equity | 136,463 | 136,165 | +0.2% |
Cash Flow Statement
| Metric | YTD Q1 2026 | YTD Q1 2025 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Depreciation | 188 | 181 | +3.9% |
| Amortization Of Intangible Assets | 1,748 | 1,858 | -5.9% |
| Deferred Income Taxes | 137 | -28 | +589.3% |
| Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 | 2,387 | 1,518 | +57.2% |
| Payment For Contingent Consideration Liability Operating Activities | -722 | -549 | -31.5% |
| Stock-Based Compensation | 444 | 410 | +8.3% |
| Non Cash Litigation Reserve Adjustments Net Of Cash Payments | 150 | -729 | +120.6% |
| Other Non-Cash Items | -22 | 17 | -229.4% |
| Change in Accounts Receivable | 87 | -1,479 | +105.9% |
| Change in Inventory | -184 | -155 | -18.7% |
| Change in Prepaid & Other Assets | -150 | -628 | +76.1% |
| Increase Decrease In Accounts Payable And Accrued Liabilities | -1,594 | -696 | -129.0% |
| Increase Decrease In Income Taxes Payable Net Of Income Taxes Receivable | -81 | 378 | -121.4% |
| Net Cash from Operations | 3,829 | 1,635 | +134.2% |
| Investing Activities | |||
| Payments To Acquire Other Investments | -266 | -334 | +20.4% |
| Capital Expenditures | -265 | -235 | -12.8% |
| Other Investing Activities | -43 | 38 | -213.2% |
| Net Cash from Investing | -574 | -735 | +21.9% |
| Financing Activities | |||
| Proceeds From Repayments Of Commercial Paper | -499 | 1,593 | -131.3% |
| Repayments Of Other Short Term Debt | -2,000 | — | — |
| Proceeds From Issuance Of Long Term Debt | 7,991 | 3,994 | +100.1% |
| Payments Of Dividends | -3,086 | -2,925 | -5.5% |
| Share Repurchases | -1,489 | -961 | -54.9% |
| Proceeds From Payments For Other Financing Activities | 2 | 67 | -97.0% |
| Net Cash from Financing | 919 | -1,258 | +173.1% |
| Other Cash Flow | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | -12 | 9 | -233.3% |
| Net Change in Cash | 4,162 | -349 | +1292.6% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 9,391 | 5,175 | +81.5% |
Values in millions USD. Source: SEC EDGAR 10-Q filing.